Flexsteel Announces Change to Board of Directors
DUBUQUE, Iowa--(BUSINESS WIRE)--Flexsteel Industries, Inc. (NASDAQ:FLXS) ('Flexsteel' or the 'Company'), one of the largest manufacturers, importers and marketers of residential furniture products in the United States, today announced the appointment of Terence P. Calloway as an independent director of the Company effective May 21, 2025.
Mr. Calloway is a global executive who is known to create competitive advantages that leverage technology and modern manufacturing processes to drive value creation, propel product innovation, and enhance profitability of globally recognized brands. He has served in multiple public companies including Energizer, Colgate-Palmolive, and Procter & Gamble.
'We are excited to have Terence join our Board of Directors. He brings considerable product innovation, supply chain, organizational leadership, and strategic planning experience, and his guidance will be invaluable as we execute our plan to better serve our customers, generate profitable growth, and improve shareholder returns,' said Flexsteel Chairman Thomas M. Levine. 'Terence's experience driving product innovation and supply chain excellence gives us confidence that he will be a great addition to our Board.'
Flexsteel CEO Derek Schmidt added, 'We are fortunate to have Terence join the Flexsteel Board of Directors. He has a distinct set of skills and experiences that will help us continue executing the Company's growth strategy. Terence has deep consumer product innovation experience and has strategically utilized supply chains to achieve a competitive advantage. His background and experience complement the strength and expertise of our board members, and I am looking forward to his guidance and working with him closely.'
Professional Background of Terence P. Calloway
Terence P. Calloway served as Executive Vice President, Global Product Supply, with Energizer Holdings, Inc, one of the largest and most recognized manufacturers of batteries in the marketplace. Mr. Calloway joined Energizer in 2015 and led a global team of over 4,100 employees within the manufacturing, engineering, quality, research and development, procurement, supply chain, and real estate functions prior to his retirement in April, 2025. Prior to Energizer, Mr. Calloway served as Director, Global Design and Package Development for Colgate-Palmolive Company, where he oversaw the global design and packaging program for the $35 billion home care category from 2014-2015. Prior to Colgate-Palmolive, Mr. Calloway served as Leader, Research and Development/Director, R&D and Glad Joint Venture for The Procter & Gamble Company, a manufacturer of products that sells consumer home and personal care packaged goods under globally-recognized household brands including Head & Shoulders, Pantene, Olay, Oral-B, Gillette, Crest, Vicks, Tide, Cascade, Febreze, Pampers, Charmin, and Swiffer. Mr. Calloway joined The Procter & Gamble Company in 1987 and held multiple positions with increasing levels of responsibility within the research and development function.
About Flexsteel
Flexsteel Industries, Inc., and Subsidiaries (the 'Company') is one of the largest manufacturers, importers, and marketers of residential furniture products in the United States. Product offerings include a wide variety of furniture such as sofas, loveseats, chairs, reclining rocking chairs, swivel rockers, sofa beds, convertible bedding units, occasional tables, desks, dining tables and chairs, kitchen storage, bedroom furniture, and outdoor furniture. A featured component in most of the upholstered furniture is a unique steel drop-in seat spring from which the name 'Flexsteel' is derived. The Company distributes its products throughout the United States through its e-commerce channel and direct sales force.
For more information, visit our website at http://www.flexsteel.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Elon Musk Says Humanoid Robots Will Start Impacting Countries' GDPs In 4 To 5 Years. 'Robot Cars' Even Sooner—In Just 1 To 2 Years
Tesla (NASDAQ:TSLA) CEO Elon Musk is doubling down on his belief that artificial intelligence and robotics will reshape the global economy—and soon. 'Accelerating GDP growth is essential,' Musk posted on X on May 23. He claimed that the U.S. government's overspending could result in a financial crisis unless there's a massive jump in productivity. He did, however, mention that the Department of Government Efficiency 'has and will do great work to postpone the day of bankruptcy of America.' Don't Miss: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. Hasbro, MGM, and Skechers trust this AI marketing firm — The X post came in response to someone wondering whether 'Elon has somewhat moved away from politics in order to accelerate GDP growth with humanoid robots' after another person wrote that 'Given the disastrous GOP bill, the only chance the US has is explosive GDP growth.' When asked how soon humanoid robots could start affecting 'the GDP of any country,' Musk replied, '4 to 5 years.' He added that 'robot cars' using Tesla's Full Self-Driving technology, could have a 'noticeable effect' within one to two years. In an interview with Sen. Ted Cruz (R-TX) in March, Musk said that within 10 years, 'AI could probably do anything better than the human can cognitively,' and predicted a future where humanoid robots are as common as personal assistants. 'Ultimately, there will be tens of billions,' he said. He also predicted that 90% of all miles driven could be autonomous within a decade. 'Goods and services will become close to free,' Musk told Cruz. 'It's not that people will have a lower standard of living, they'll have actually a much higher standard of living.' Trending: Earlier this month, Musk showcased Tesla's Optimus humanoid robots to Saudi Crown Prince Mohammed bin Salman and President Donald Trump during a demonstration in Riyadh. The robots even danced to 'YMCA.' 'I think they were very impressed,' Musk said at a Saudi economic forum. He also joked that one of the robots performed the 'Trump dance.' Musk envisions a world where humanoid robots are everywhere, calling them personal versions of 'Star Wars' robots C-3PO or R2-D2. He believes robotics could create an economy '10 times the size of the current global economy' and result in 'universal high income.' Still, challenges remain. During a recent Tesla earnings call, Musk admitted that supply chain issues—including China's export restrictions on rare earth magnets—are slowing down Optimus some experts have questioned Musk's timelines regarding FSD. AI pioneer Yann LeCun, for instance, accused Musk last year of lying for years about the capabilities of Tesla's FSD technology. In September, he posted on X, 'Elon: 'I've kept lying to you again and again about Tesla's 'Full Self Driving' capabilities for the last 8 years, but you should believe everything I say about politics and everything else.'' LeCun was responding to an article by Green Hills Software CEO Dan O'Dowd, who called Musk a 'snake oil salesman' for failing to deliver promised features like 'Actually Smart Summon.' Musk, however, continues to press forward, making it known he believes AI and robotics aren't just the future—they're the last hope to prevent economic collapse. He also recently confirmed that Tesla is on track to rollout fully-autonomous vehicles in Austin, Texas, in June. Read Next: Here's what Americans think you need to be considered wealthy. Deloitte's fastest-growing software company partners with Amazon, Walmart & Target – Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? TESLA (TSLA): Free Stock Analysis Report This article Elon Musk Says Humanoid Robots Will Start Impacting Countries' GDPs In 4 To 5 Years. 'Robot Cars' Even Sooner—In Just 1 To 2 Years originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Miami Herald
2 hours ago
- Miami Herald
Tempus AI hits back at scathing short report
On May 28, Tempus AI (TEM) stock plunged as the market reacted to a damning report from short seller Spruce Point Capital. One day later, the company responded to the accusations against it. A company at the intersection of healthcare and artificial intelligence (AI), Tempus began trading on the Nasdaq in June 2024, a year that didn't see too many high-profile initial public offerings (IPOs). For that reason, Tempus stood out, and investors were hungry for new AI stocks to buy. Don't miss the move: Subscribe to TheStreet's free daily newsletter While trading has been fairly volatile, TEM stock has mostly risen and is currently up 35% for the year. Since 2025 began, its performance has been quite strong, with year-to-date (YTD) gains of almost 60%. The damning short report from Spruce Point Capital pushed shares down this week, although TEM stock has since recovered. Tempus took the opportunity to respond to short sellers' claims and offer its own take on the allegations. Since its founding in 2009, Spruce Point Capital has released over 100 forensic short reports, laying out cases against companies across various industries. In April 2025, it revealed short positions in travel tech company Clear Secure and popular beverage producer Monster Energy. Related: Billionaire fund manager, skeptical of AI, backs shocking stock Most recently, though, it published a detailed short report that revealed a bet against Tempus stock. In it, the short-seller estimated that TEM stock posed a "50%-60% potential long-term downside and market underperformance risk" for investors, primarily due to concerns regarding its leadership and AI capabilities. For context, Tempus uses AI to improve precision medicine solutions, as well as drug discovery and diagnostics. Its operating system is reported to analyze medical information and make it accessible for patients, as well as doctors and scientific researchers. However, Spruce Point's researchers make it clear in the report that they harbor grave concerns about the AI hype surrounding TEM stock, suggesting that it may be significantly overblown. The short seller also discusses Tempus founder and CEO Eric Lefkofsky, highlighting comparisons he has drawn to his company and market leaders such as Tesla and Nvidia. "He suggests that Tempus is likely to reach a similar inflection point, and that vast upside is around the corner. However, 10 years since being founded in 2015, there is no evidence that Tempus has generated a profit or net positive cash flow," Spruce Point notes. More AI News: OpenAI teams up with legendary Apple execMajor AI CEO sounds alarm on jobless 'bloodbath' in near-termSalesforce makes a big bet on booming tech market The report raises the point that after a decade of operation, both Tesla and Nvidia had posted $2 billion in revenue and achieved at least one cash flow positive year. It notes that in 2024, only $12.4 million, roughly 2% of Tempus's yearly revenue, came from AI applications. The underlying theme of the Spruce Point short report seems to be that it believes Tempus's AI hype is overblown and poses a massive risk for investors. For that reason, TEM stock earns a Strong Sell Opinion from the firm. Related: Google hit with scathing accusations from top VC firm Not all companies respond after being targeted by a short seller, but on May 29, Tempus issued a statement on X, addressing the report. The company described Spruce Point's claims as inaccurate and misleading, encouraging investors to do their own research. "We do not intend to respond through the media to a report that is riddled with inaccuracies, conjecture, and ill-informed hypotheticals," the health care company stated. "It also fails to address Tempus' history of strong financial performance and impressive growth." Tempus also took its argument a step further, claiming that the last five stocks targeted by Spruce Point are up "on average, over 20% in the past 4 months." The company added that it stands by its results and remains committed to helping health care professionals leverage AI for the benefit of patients. Related: Legendary tech expert has unexpected view of AI impact on jobs The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Yahoo
2 hours ago
- Yahoo
LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Intrinsic Value Is Potentially 17% Below Its Share Price
Using the 2 Stage Free Cash Flow to Equity, LeMaitre Vascular fair value estimate is US$67.98 LeMaitre Vascular's US$82.20 share price signals that it might be 21% overvalued Analyst price target for LMAT is US$105, which is 54% above our fair value estimate In this article we are going to estimate the intrinsic value of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by taking the forecast future cash flows of the company and discounting them back to today's value. Our analysis will employ the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex. We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, so we discount the value of these future cash flows to their estimated value in today's dollars: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF ($, Millions) US$50.0m US$58.8m US$71.3m US$67.4m US$74.8m US$78.9m US$82.6m US$86.0m US$89.3m US$92.4m Growth Rate Estimate Source Analyst x4 Analyst x4 Analyst x2 Analyst x1 Analyst x1 Est @ 5.43% Est @ 4.69% Est @ 4.16% Est @ 3.80% Est @ 3.54% Present Value ($, Millions) Discounted @ 7.4% US$46.5 US$50.9 US$57.5 US$50.6 US$52.3 US$51.3 US$50.0 US$48.5 US$46.8 US$45.2 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$500m The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.4%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = US$92m× (1 + 2.9%) ÷ (7.4%– 2.9%) = US$2.1b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$2.1b÷ ( 1 + 7.4%)10= US$1.0b The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$1.5b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$82.2, the company appears slightly overvalued at the time of writing. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent. The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at LeMaitre Vascular as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.4%, which is based on a levered beta of 1.036. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. View our latest analysis for LeMaitre Vascular Strength Earnings growth over the past year exceeded the industry. Debt is not viewed as a risk. Dividends are covered by earnings and cash flows. Weakness Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market. Expensive based on P/E ratio and estimated fair value. Opportunity Annual earnings are forecast to grow for the next 3 years. Threat Annual earnings are forecast to grow slower than the American market. Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Why is the intrinsic value lower than the current share price? For LeMaitre Vascular, we've compiled three essential aspects you should further research: Risks: Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with LeMaitre Vascular , and understanding it should be part of your investment process. Future Earnings: How does LMAT's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered! PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Effettua l'accesso per consultare il tuo portafoglio
